Risk factor
Very high price volatility
Profitability factor
Very low or no dividends
About
PuraPharm Corporation Limited, an investment holding entity, focuses on the research, development, manufacturing, and global distribution of concentrated Chinese medicine granules (CCMG) and various Chinese healthcare products across Hong Kong, Mainland China, and international markets. Its operations are structured into five key divisions: China CCMG, Hong Kong CCMG, Chinese Healthcare Products, Clinics, and Plantation. The company offers a range of over-the-counter health solutions under brand names such as PuraGold, Haveron, Oncozac, and Immuzac. Beyond product sales, PuraPharm provides a clinic management system for general Chinese medical practices and operates its own chain of Nong's Chinese medicine clinics, which deliver both traditional medical services and CCMG products. The company also oversees the cultivation and trade of raw Chinese herbs, in addition to manufacturing and selling traditional Chinese medicine decoction pieces. Complementing its product offerings, it delivers modernized Chinese medicine services and diagnostic consultations. PuraPharm distributes its goods to hospitals, healthcare institutions, medical professionals, and directly to consumers via an online store. The company currently manages 43 Nong's clinics in Hong Kong and one in Guangxi, China. Founded in 1998, its headquarters are located in Tai Po, Hong Kong.
Company Valuation
Based on key historical and expected multiples, the stock is slightly undervalued relative to its peers. Specifically, the stock is 'cheap' on P/E, neutral on EV/EBITDA,